| Title |
Efficacy and safety of co-administration of resveratrol with meloxicam in patients with knee osteoarthritis: a pilot interventional study
|
|---|---|
| Published in |
Clinical Interventions in Aging, September 2018
|
| DOI | 10.2147/cia.s172758 |
| Pubmed ID | |
| Authors |
Saad Abdulrahman Hussain, Bushra Hassan Marouf, Ziyad Serdar Ali, Runj Simko Ahmmad |
| Abstract |
Resveratrol shows remarkable anti-inflammatory activities in experimental models. This study aims to evaluate the effect of resveratrol, as an adjuvant with meloxicam (Mlx), on the pain and functional activity during a 90-day period and monitor the adverse effects on kidney and liver functions, lipid profile, and hematological markers. This study was a double-blind, placebo-controlled, randomized multi-center study that involved 110 patients with knee osteoarthritis (OA) and was performed at Sulaimani City, Iraq, from December 2016 to September 2017. To assess the effects of Mlx with or without resveratrol, pain severity and functional disability were evaluated at baseline and after 90 days using the Western Ontario and McMaster Universities Osteoarthritis Index. Fasting blood was collected to evaluate the lipid profile markers, hematological picture, and liver and kidney functions, in addition to vitamin D level. Resveratrol significantly improves pain, functions, and associated symptoms compared with placebo. The clinical and biochemical markers indicated that 500 mg/day of resveratrol, as an adjuvant with Mlx, is safe and well tolerated by the knee OA patients. Resveratrol, as an "add-on" medication with Mlx, was superior in terms of safety and efficacy to Mlx alone for the treatment of pain and improvement of physical function in patients with knee OA. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Australia | 2 | 67% |
| United Kingdom | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 101 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 12% |
| Researcher | 9 | 9% |
| Other | 8 | 8% |
| Student > Ph. D. Student | 8 | 8% |
| Student > Bachelor | 6 | 6% |
| Other | 16 | 16% |
| Unknown | 42 | 42% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 24% |
| Nursing and Health Professions | 9 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 7% |
| Agricultural and Biological Sciences | 4 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Other | 9 | 9% |
| Unknown | 45 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 September 2018.
All research outputs
#14,789,745
of 25,385,509 outputs
Outputs from Clinical Interventions in Aging
#959
of 1,968 outputs
Outputs of similar age
#174,735
of 345,739 outputs
Outputs of similar age from Clinical Interventions in Aging
#30
of 55 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,968 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 345,739 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 55 others from the same source and published within six weeks on either side of this one. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.